In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
The antimicrobial effects of a new dihydrofolate reductase inhibitor, epiroprim, alone and in combination with dapsone and brodimoprim against Mycobacterium leprae were evaluated in vitro in cell-free culture system. Two biochemical parameters were used to measure metabolic activity (and growth) of the organism. The minimal inhibitory activity of epiroprim against M. leprae was 10 mg/l and the action was bactericidal. When combined with dapsone, epiroprim exhibited a strong synergism; on the other hand, combination of epiroprim and brodimoprim provided only additive effects. The results suggest that epiroprim can be a component in multidrug therapy regimen in leprosy.
Dhople
A M
AM
Department of Biological Sciences, Florida Institute of Technology, Melbourne 32901, USA. adhople@fit.edu
D002474:Cell-Free System; D003622:Dapsone / Q000008:administration & dosage*; D005493:Folic Acid Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D007917:Leprostatic Agents / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000254:growth & development; D014295:Trimethoprim / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D005493:Folic Acid Antagonists; D007917:Leprostatic Agents; D003622:Dapsone; C082896:epiroprim; D014295:Trimethoprim; C037079:brodimoprim